{
    "nctId": "NCT02948751",
    "briefTitle": "Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer",
    "officialTitle": "Pilot Study Evaluating the Utility of OncoCEE (Cell Enrichment and Extraction) Technology, a Novel Immunocytochemical Microfluidic Device, in the Diagnosis of Leptomeningeal Metastasis (LM) From Breast Cancer Through Identification of Circulating Tumor Cells (CTCs) in Cerebrospinal Fluid (CSF)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Leptomeningeal Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "N/A",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult (18 years or older) patients, with invasive breast cancer, of all racial and ethnic origins\n* Undergoing lumbar puncture for clinical or radiographic suspicion of leptomeningeal metastasis\n* Provide study-specific informed consent\n* Patients with unequivocal or suspicious MRI findings.\n* Of those with a definitive diagnosis of LM (i.e. positive CSF cytology), 10 evaluable patients will be accrued.\n\nExclusion Criteria:\n\n* Prior CSF fluid which identified malignant cells after 10 evaluable patients with positive CSF are accrued.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}